WO2006044665A3 - Neuroprotective spirostenol pharmaceutical compositions - Google Patents
Neuroprotective spirostenol pharmaceutical compositions Download PDFInfo
- Publication number
- WO2006044665A3 WO2006044665A3 PCT/US2005/037023 US2005037023W WO2006044665A3 WO 2006044665 A3 WO2006044665 A3 WO 2006044665A3 US 2005037023 W US2005037023 W US 2005037023W WO 2006044665 A3 WO2006044665 A3 WO 2006044665A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- spirostenol
- neuroprotective
- pharmaceutical compositions
- neurotoxicity
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002584333A CA2584333A1 (en) | 2004-10-14 | 2005-10-14 | Neuroprotective spirostenol pharmaceutical compositions |
JP2007536942A JP2008516972A (en) | 2004-10-14 | 2005-10-14 | Pharmaceutical composition of spirostenol having neuroprotective action |
AU2005295617A AU2005295617A1 (en) | 2004-10-14 | 2005-10-14 | Neuroprotective spirostenol pharmaceutical compositions |
EP05812949A EP1809298A4 (en) | 2004-10-14 | 2005-10-14 | Neuroprotective spirostenol pharmaceutical compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61869604P | 2004-10-14 | 2004-10-14 | |
US60/618,696 | 2004-10-14 | ||
US11/031,538 | 2005-01-07 | ||
US11/031,538 US20060009433A1 (en) | 2003-03-14 | 2005-01-07 | Neuroprotective spirostenol pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006044665A2 WO2006044665A2 (en) | 2006-04-27 |
WO2006044665A3 true WO2006044665A3 (en) | 2007-07-05 |
Family
ID=36203560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/037023 WO2006044665A2 (en) | 2004-10-14 | 2005-10-14 | Neuroprotective spirostenol pharmaceutical compositions |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1809298A4 (en) |
JP (1) | JP2008516972A (en) |
AU (1) | AU2005295617A1 (en) |
CA (1) | CA2584333A1 (en) |
WO (1) | WO2006044665A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006231451A1 (en) * | 2005-04-01 | 2006-10-12 | Georgetown University | Use of spirostenols to treat mitochondrial disorders |
GB0619860D0 (en) * | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
WO2015163318A1 (en) * | 2014-04-25 | 2015-10-29 | レジリオ株式会社 | Therapeutic agent for diseases associated with nerve axon dysfunction, including therapeutic agent for alzheimer's disease |
WO2024024395A1 (en) * | 2022-07-29 | 2024-02-01 | 国立大学法人富山大学 | Pharmaceutical or food and beverage composition for prevention or treatment of optic nerve disorder |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4303214A1 (en) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones |
WO1999048507A2 (en) * | 1998-03-26 | 1999-09-30 | Phytopharm Plc | Steroidal saponins for treating alzheimer's disease |
WO2002011708A2 (en) * | 2000-08-04 | 2002-02-14 | Symphar S.A. | Methods for inducing apolipoprotein e secretion |
US6593301B1 (en) * | 1997-09-26 | 2003-07-15 | Institute Of Radiation Medicine | Use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1496913A4 (en) * | 2002-03-15 | 2007-10-31 | Samaritan Pharmaceuticals Inc | Neuroprotective spirostenol pharmaceutical compositions |
AU2003231427A1 (en) * | 2002-04-15 | 2003-10-27 | Chengdu Di'ao Pharmaceutical Group Co., Ltd. | Compounds and preparation methods of carboxylate and monoester succinate derivative of diosgenin |
-
2005
- 2005-10-14 WO PCT/US2005/037023 patent/WO2006044665A2/en active Application Filing
- 2005-10-14 JP JP2007536942A patent/JP2008516972A/en not_active Withdrawn
- 2005-10-14 CA CA002584333A patent/CA2584333A1/en not_active Abandoned
- 2005-10-14 AU AU2005295617A patent/AU2005295617A1/en not_active Abandoned
- 2005-10-14 EP EP05812949A patent/EP1809298A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4303214A1 (en) * | 1993-02-04 | 1994-08-11 | Wolfgang Marks | Treatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones |
US6593301B1 (en) * | 1997-09-26 | 2003-07-15 | Institute Of Radiation Medicine | Use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds |
WO1999048507A2 (en) * | 1998-03-26 | 1999-09-30 | Phytopharm Plc | Steroidal saponins for treating alzheimer's disease |
WO2002011708A2 (en) * | 2000-08-04 | 2002-02-14 | Symphar S.A. | Methods for inducing apolipoprotein e secretion |
Non-Patent Citations (2)
Title |
---|
See also references of EP1809298A4 * |
YAO ET AL.: "22R-Hydroxycholesterol Protects Neuronal Cells from Beta-Amyloid-Induced Cytotoxicity by Binding to Beta-Amyloid Peptide", JOURNAL OF NEUROCHEMISTRY, vol. 83, 2002, pages 1110 - 1119, XP003015166 * |
Also Published As
Publication number | Publication date |
---|---|
EP1809298A4 (en) | 2008-06-18 |
WO2006044665A2 (en) | 2006-04-27 |
AU2005295617A1 (en) | 2006-04-27 |
EP1809298A2 (en) | 2007-07-25 |
JP2008516972A (en) | 2008-05-22 |
CA2584333A1 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
WO2006124012A3 (en) | Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptide production | |
EP2331095A4 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
MX2014002459A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. | |
AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
UA94909C2 (en) | Pharmaceutical composition of a neuroactive steroid and use thereof | |
WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
WO2002043652A3 (en) | Anti-proliferative drugs | |
WO2005115432A3 (en) | Treatment of ocular diseases and disorders using lantibiotic compositions | |
BRPI0712322A2 (en) | compounds and combinations thereof for inhibiting beta-amyloid production and methods of using them | |
NZ596244A (en) | Treatment of neurodegenerative diseases | |
WO2002096415A3 (en) | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease | |
WO2006081431A3 (en) | Compounds for treating inflammatory and demyelinating diseases | |
WO2008122441A3 (en) | Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases | |
WO2005121778A3 (en) | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases | |
WO2010042489A3 (en) | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use | |
WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
WO2006083797A3 (en) | Improving and protecting cell therapy for neurological disorders including parkinson's disease | |
WO2008063768A3 (en) | Compositions and methods for treating metabolic diseases | |
WO2007098047A3 (en) | Methods and compositions for the treatment of parkinson's disease | |
WO2006044665A3 (en) | Neuroprotective spirostenol pharmaceutical compositions | |
WO2005072704A3 (en) | Method of treating acute rhinosinusitis | |
IL167848A (en) | Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions | |
WO2006101909A3 (en) | Combination therapy for treating or preventing diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007536942 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2584333 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005295617 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005812949 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005295617 Country of ref document: AU Date of ref document: 20051014 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580042630.4 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005812949 Country of ref document: EP |